Targeting the JAK/STAT pathway in solid tumors

Abstract

Aberrant activation of signal transducer and activator of transcription (STAT) proteins is associated with the development and progression of solid tumors. However, as transcription factors, these proteins are difficult to target directly. In this review, we summarize the role of targeting Janus kinases (JAKs), upstream activators of STATs, as a strategy for decreasing STAT activation in solid tumors. Preclinical studies in solid tumor cell line models show that JAK inhibitors decrease STAT activation, cell proliferation, and cell survival; in in vivo models, they also inhibit tumor growth. JAK inhibitors, particularly the JAK1/2 inhibitor ruxolitinib, sensitize cell lines and murine models to chemotherapy, immunotherapy, and oncolytic viral therapy. Ten JAK inhibitors have been or are actively being tested in clinical trials as monotherapy or in combination with other agents in patients with solid tumors; two of these inhibitors are already Food and Drug Administration (FDA) approved for the treatment of myeloproliferative disorders and rheumatoid arthritis, making them attractive agents for use in patients with solid tumors as they are known to be well-tolerated. Four JAK inhibitors (two of which are FDA approved for other indications) have exhibited promising anti-cancer effects in preclinical studies; however, clinical studies specifically assessing their activity against the JAK/STAT pathway in solid tumors have not yet been conducted. In summary, JAK inhibition is a viable option for targeting the JAK/STAT pathway in solid tumors and merits further testing in clinical trials.

Keywords

Clinical trials / Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway / JAK inhibitors / solid tumors / STAT hyperactivation

References

[1] Thomas SJ,Zeidler MP.The role of JAK/STAT jnsignalling in the pathogenesis, prognosis and treatment of solid tumours..Br J Cancer2015;113:365-71 PMCID:PMC4522639

[2] O’Shea JJ,Staudt LM.JAKs and STATs in Immunity, Immunodeficiency, and Cancer..N Engl J Med2013;368:161-70

[3] O’Sullivan JM.JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplas ms..Mol Cell Endocrinol2017;451:71-9

[4] Khanna P,Sereemaspun A,Baeg GH.GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling..Sci Rep2018;8:9511 PMCID:PMC6015000

[5] Haque I,Acup S,Dhar K.Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway..BMC Cancer2018;18:99 PMCID:PMC5785848

[6] Lokau J,Haybaeck J.Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma..Cancers (Basel)2019;11:1704 PMCID:PMC6896168

[7] Grandis JR,Zeng Q,Melhem MF.Constitutive activation of stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo..Proc Natl Acad Sci U S A2000;97:4227-32 PMCID:PMC18206

[8] Wu CS,Chou JL,Hsieh CC.Aberrant JAK/STAT signaling suppresses TFF1 and TFF2 through epigenetic silencing of GATA6 in gastric cancer..Int J Mol Sci2016;17:1467 PMCID:PMC5037745

[9] Shang AQ,Bi F,Xu LR.Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer..Cancer Biol Ther2017;18:314-22 PMCID:PMC5499756

[10] Nishi M,Yoshikawa K,Tokunaga T.High STAT4 expression indicates better disease-free survival in patients with gastric cancer..Anticancer Res2017;37:6723-9

[11] Nikitakis N,Sauk J.Targeting the STAT pathway in head and neck cancer: recent advances and future prospects..Curr Cancer Drug Targets2005;4:637-51

[12] Khanna P,Bay BH.The JAK/STAT signaling cascade in gastric carcinoma (Review)..Int J Oncol2015;47:1617-26

[13] Tabassum S,Ahmad N.Targeting of JAK-STAT signaling in breast cancer: therapeutic strategies to overcome drug resistance..Adv Exp Med Biol2019;1152:271-81

[14] Vainchenker W.JAK/STAT signaling in hematological malignancies..Oncogene2013;32:2601-13

[15] Kralovics R,Buser AS,Tiedt R.A gain-of-function mutation of JAK2 in myeloproliferative disorders..N Engl J Med2005;352:1779-90

[16] Plosker GL.Ruxolitinib: a review of its use in patients with myelofibrosis..Drugs2015;75:297-308

[17] Verstovsek S,Gotlib J,Gupta V.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis..N Engl J Med2012;366:799-807 PMCID:PMC4822164

[18] Harrison CN,Kiladjian JJ,Gisslinger H.Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis..Leukemia2016;30:1701-7 PMCID:PMC5399157

[19] Vannucchi AM,Griesshammer M,Durrant S.Ruxolitinib versus standard therapy for the treatment of polycythemia vera..N Engl J Med2015;372:426-35 PMCID:PMC4358820

[20] Vannucchi AM,Guglielmelli P,Burn TC.Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study..Ann Hematol2017;96:1113-20 PMCID:PMC5486779

[21] Verstovsek S,Rambaldi A,Rosen PJ.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea..Cancer2014;120:513-20 PMCID:PMC4231215

[22] Verstovsek S,Griesshammer M,Durrant S.Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial..Haematologica2016;101:821-9 PMCID:PMC5004461

[23] Morris R,Babon JJ.The molecular details of cytokine signaling via the JAK/STAT pathway..Protein Sci2018;27:1984-2009 PMCID:PMC6237706

[24] Rawlings JS,Harrison DA.The JAK/STAT signaling pathway..J Cell Sci2004;117:1281-3

[25] Liongue C.Evolution of the JAK-STAT pathway..JAK-STAT2013;2:e22756 PMCID:PMC3670263

[26] Lim CP.Structure, function, and regulation of STAT proteins..Mol Biosyst2006;2:536-50

[27] Alvarez JV,Alvarez J.Genome-wide analysis of STAT target genes: Elucidating the mechanism of STAT-mediated oncogenesis..Cancer Biol Ther2004;3:1045-50

[28] Wang Y,Wang S,Zhou X.The role of STAT3 in leading the crosstalk between human cancers and the immune system..Cancer Lett2018;415:117-28 PMCID:PMC5748258

[29] Greenhalgh CJ.Negative regulation of cytokine signaling..J Leukoc Biol2001;70:348-56

[30] Chikuma S,Mise-Omata S.Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy..Cancer Sci2017;108:574-80 PMCID:PMC5406529

[31] Niu GJ,Yuan WJ,Yang MC.Protein inhibitor of activated STAT (PIAS) negatively regulates the JAK/STAT pathway by inhibiting STAT phosphorylation and translocation..Front Immunol2018;9:2392 PMCID:PMC6212522

[32] Frankson R,Bai Y,Zhang RY.Therapeutic targeting of oncogenic tyrosine phosphatases..Cancer Res2017;77:5701-5 PMCID:PMC5827927

[33] Kim M,Jang IS,Kim DJ.Protein tyrosine phosphatases as potential regulators of STAT3 signaling..Int J Mol Sci2018;19:2708 PMCID:PMC6164089

[34] Chen YW,Shen L,Tao Q.Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma..Blood2015;125:1589-600

[35] Lee M,Eu JQ,Wang L.Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors..Redox Biol2019;25:101073 PMCID:PMC6859582

[36] Zhang X,Yu J,Chen Y.Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T..Proc Natl Acad Sci U S A2007;104:4060-4 PMCID:PMC1802729

[37] Veeriah S,Meng S,Fagin JA.The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers..Proc Natl Acad Sci U S A2009;106:9435-40 PMCID:PMC2687998

[38] Shahmarvand N,Shahryari J.Mutations in the signal transducer and activator of transcription family of genes in cancer..Cancer Sci2018;109:926-33 PMCID:PMC5891179

[39] Shi M,Feldman AL,Jevremovic D.STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia..Hum Pathol2018;73:74-81

[40] Yang S,Gu Q,Wang G.Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma..Oncotarget2016;7:5461-9 PMCID:PMC4868698

[41] Kan Z,Liu X,Barber TD.Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma..Genome Res2013;23:1422-33 PMCID:PMC3759719

[42] Igelmann S,Ferbeyre G.STAT3 and STAT5 activation in solid cancers..Cancers (Basel)2019;11:1428 PMCID:PMC6826753

[43] Orlova A,De Araujo ED,Neubauer HA.Direct targeting options for STAT3 and STAT5 in cancer..Cancers (Basel)2019;11:1930 PMCID:PMC6966570

[44] Wang Y,Zhang C,Zhu T.TGF-β-induced STAT3 overexpression promotes human head and neck squamous cell carcinoma invasion and metastasis through malat1/miR-30a interactions..Cancer Lett2018;436:52-62

[45] Kijima T,Steinman RA,Gooding WE.STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo..Cell Growth Differ2002;13:355-62

[46] Bu LL,Wu L,Deng WW.STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC..J Dent Res2017;96:1027-34 PMCID:PMC6728673

[47] Kanda N,Konda Y,Kanai M.STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells..Oncogene2004;23:4921-9

[48] Wu X,Zhou Q,Yu Z.IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway..Oncotarget2017;8:20741-50 PMCID:PMC5400541

[49] Pan YM,Zhu M,Cui JT.STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer..Mol Cancer2016;15:79 PMCID:PMC5148878

[50] Shien K,Ruder D,Shen L.JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer..Mol Cancer Ther2017;16:2234-45 PMCID:PMC5628136

[51] He W,Shi J,Dai W.IL22RA1/STAT3 signaling promotes stemness and tumorigenicity in pancreatic cancer..Cancer Res2018;78:3293-305

[52] Lu C,Savage NM,Liu K.JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer..Oncoimmunology2017;6:e1291106 PMCID:PMC5384417

[53] Lin XM,Zhan XL.MIR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3..Eur Rev Med Pharmacol Sci2019;23:6906-13

[54] Peyser ND,Wang L,Li H.Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer..Oncogene2016;35:1163-9 PMCID:PMC4651851

[55] Peyser ND,Li H,Xiao X.Loss-of-function PTPRD mutations lead to increased STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer..PLoS One2015;10:e0135750 PMCID:PMC4534317

[56] Gyamfi J,Eom M.Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells..Sci Rep2018;8:8859 PMCID:PMC5995871

[57] Jiang C,Liu B,Wang W.miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma..J Exp Clin Cancer Res2017;36:99 PMCID:PMC5532790

[58] Saini U,Elnaggar AC,Wallbillich JJ.Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target..Oncogene2017;36:168-81 PMCID:PMC5338638

[59] Escher TE,Geanes ES,Tawfik O.Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis..Mol Cancer Res2019;17:1180-94 PMCID:PMC6497545

[60] Chen X,Yuchun L.High expression of STAT2 in ovarian cancer and its effect on metastasis of ovarian cancer cells..Nan Fang Yi Ke Da Xue Xue Bao2020;40:34-41(in Chinese) PMCID:PMC7040754

[61] Yang M,Zhou L,Su F.Expression profile and prognostic values of STAT family members in non-small cell lung cancer..Am J Transl Res2019;11:4866-80 PMCID:PMC6731411

[62] Haddad BR,Udhane V,Rone JD.Positive STAT5 protein and locus amplification status predicts recurrence after radical prostatectomy to assist clinical precision management of prostate cancer..Cancer Epidemiol Biomarkers Prev2019;28:1642-51 PMCID:PMC6774884

[63] Liao Z,Nevalainen MT.Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer..Int J Biochem Cell Biol2010;42:186-92 PMCID:PMC2818495

[64] Li BH,Li PD,Liu XH.IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells..Biochem Biophys Res Commun2008;369:554-60

[65] von Bubnoff N,Grishina O,Bertz H.Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versushost disease (aGvHD) (NCT02396628)..BMC Cancer2018;18:1132 PMCID:PMC6245867

[66] Lim ST,Gwak H,Suh YJ.Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells..Mol Med Rep2018;17:5581-8 PMCID:PMC5865997

[67] Kim JW,Kim JE,Kang KW.Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor..Oncol Lett2019;17:3981-9 PMCID:PMC6425385

[68] Taverna JA,DeArmond DT,Lin CL.Single-cell proteomic profiling identifies combined AXL and JAK1 inhibition as a novel therapeutic strategy for lung cancer..Cancer Res2020;80:1551-63 PMCID:PMC7127959

[69] Vallath S,Kolluri KK,Teixeira VS.CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity..Sci Rep2016;6:24006 PMCID:PMC4817512

[70] Yang PW,Yong LS,Wu CW.Circulating interleukin-6 is associated with prognosis and genetic polymorphisms of MIR608 in patients with esophageal squamous cell carcinoma..Ann Surg Oncol2018;25:2449-56

[71] Ojha R,Bhattacharyya S.JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells..Biochim Biophys Acta - Gen Subj2016;1860:2484-97

[72] Wilson GS,Hebbard L,George J.Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro..Cancer Lett2013;341:224-30

[73] Morgan EL.JAK2 inhibition impairs proliferation and sensitises cervical cancer cells to cisplatin-induced cell death..Cancers (Basel)2019;11:1934 PMCID:PMC6966458

[74] An HJ,Kim JS,Moon JH.INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells..Neoplasma2014;61:56-62

[75] Radhakrishnan H,Walther W,Sasazuki T.MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers..Cancer Lett2017;403:231-45

[76] Gore J,Wilson JL,Cheng M.TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis..Oncotarget2015;6:7504-21 PMCID:PMC4480696

[77] Perusina Lanfranca M,Girgis A,Lazarus J.Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice..Gastroenterology2020;158:1417-32.e11 PMCID:PMC7197347

[78] Borriello L,Sheard MA,Sposto R.Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells..Cancer Res2017;77:5142-57 PMCID:PMC5600847

[79] Hadjidaniel MD,Hung LT,Shirinbak S.Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC..Oncotarget2017;8:91516-29 PMCID:PMC5710942

[80] Mohrherr J,Breitenecker K,Moritsch S.JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression..Int J Cancer2019;145:3376-88 PMCID:PMC6856680

[81] Hu Y,Xu Y,Guo DH.Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in nonsmall-cell lung cancer NSCLC..Apoptosis2014;19:1627-36

[82] Dolatabadi S,Lindén M,Bäcksten K.JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma..Int J Cancer2019;145:435-49 PMCID:PMC6590236

[83] McLean K,Bolland DE,Peterson LF.Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth..Oncogene2019;38:1576-84 PMCID:PMC6374186

[84] Reeves PM,Kools FRW,Tong X.Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice..Oncotarget2017;8:94040-53 PMCID:PMC5706854

[85] Escobar-Zarate D,Suksanpaisan L,Peng KW.Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors..Cancer Gene Ther2013;20:582-9 PMCID:PMC4817541

[86] Cataldi M,Felt SA.Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1..Virology2015;485:340-54 PMCID:PMC4619123

[87] Kurokawa C,Anderson SK,Leontovich AA.Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy..J Natl Cancer Inst2018;110:1123-32 PMCID:PMC6186520

[88] Patel MR,Jacobson BA,Baumann D.JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in nonsmall cell lung cancer models..Cancer Gene Ther2019;26:411-8

[89] Hurwitz HI,Wagner SA,Beck JT.Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed..J Clin Oncol2015;33:4039-47 PMCID:PMC5089161

[90] Hurwitz H,Bendell J,Li CP.Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies..Invest New Drugs2018;36:683-95 PMCID:PMC6752723

[91] O’Shaughnessy J,Ma CX,Yardley DA.A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation..Breast Cancer Res Treat2018;170:547-57

[92] Stover DG,Brock J,Overmoyer B.Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer..NPJ Breast Cancer2018;4:10 PMCID:PMC5935675

[93] Eisenhauer EA,Bogaerts J,Sargent D.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)..Eur J Cancer2009;45:228-47

[94] Fogelman D,García-Alfonso P,Nemunaitis J.Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer..Cancer Med2018;7:5382-93 PMCID:PMC6246927

[95] Giaccone G,Waqar SN,Ponce S.A placebo-controlled phase II study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer and systemic inflammation..Clin Lung Cancer2018;19:e567-74

[96] Park JS,Chun YJ,Cho BC.A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs..Lung Cancer2019;134:46-51

[97] Yu HA,Chang Q,Kris MG.A phase 1/2 trial of Ruxolitinib and Erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to Erlotinib..J Thoracic Oncol2017;12:102-9 PMCID:PMC5552054

[98] Bauer TM,Forero-Torres A,Assad A.Aphase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors..Onco Targets Ther2018;11:2399-407 PMCID:PMC5935192

[99] Sandborn WJ,Sands BE,Vermeire S.Tofacitinib as induction and maintenance therapy for ulcerative colitis..N Engl J Med2017;376:1723-36

[100] Lee EB,Hall S,Bradley JD.Tofacitinib versus methotrexate in rheumatoid arthritis..N Engl J Med2014;370:2377-86

[101] Fleischmann R,Hall S,Moots RJ.Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial..Lancet2017;390:457-68

[102] Fleischmann R,Cush J,Connell CA.Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis..N Engl J Med2012;367:495-507

[103] Lapeire L,Lambein K,Braems G.Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling..Cancer Res2014;74:6806-19

[104] Seol MA,Oh K,Seo MW.Interleukin-7 Contributes to the invasiveness of prostate cancer cells by promoting epithelial-mesenchymal transition..Sci Rep2019;9:6917 PMCID:PMC6502845

[105] McFarland BC,Langford CP,Yu H.Therapeutic potential of AZD1480 for the treatment of human glioblastoma..Mol Cancer Ther2011;10:2384-93Page 16 of 18 Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58 PMCID:PMC3237864

[106] Wang T,Lee H,Tripathi SC.JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance..Cell Metab2018;27:136-50.e5 PMCID:PMC5777338

[107] Chang Q,Sansone P,Gao SP.The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis..Neoplasia (United States)2013;15:848-62 PMCID:PMC3689247

[108] Sen M,Black J,Wheeler S.JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth..Neoplasia2015;17:256-64 PMCID:PMC4372647

[109] Wen W,Liu L,Buettner R.Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer..Mol Cancer2015;14:100 PMCID:PMC4437681

[110] Plimack ER,McCoon P,Krebs AD.AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors..Oncologist2013;18:819-20 PMCID:PMC3720635

[111] Su Q,Bebernitz G,Borenstein CF.Discovery of (2R)-N-[3-[2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino] pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus Kinase 1 (JAK1) inhibitor..J Med Chem2020;63:4517-27

[112] Sanchez E,Patil S,Nosrati JD.The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo..Ann Hematol2019;98:691-703

[113] Stubbs MC,Sparks R,Diamond S.The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies..Clin Cancer Res2019;25:300-11

[114] Beatty GL,Beck T,Cohen SJ.A phase Ib/II study of the JAK1 inhibitor, itacitinib, plus nab -paclitaxel and gemcitabine in advanced solid tumors..Oncologist2019;24:14 PMCID:PMC6324630

[115] Xu L,Gao G.Momelotinib for the treatment of myelofibrosis..Expert Opin Pharmacother2019;20:1943-51

[116] Burns CJ,Andrau L,Charman SA.Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)..Bioorganic Med Chem Lett2009;19:5887-92

[117] Chan E,Burns C,Findlay JK.Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer..Oncotarget2018;9:16599-618 PMCID:PMC5908273

[118] Abubaker K,Escalona R,Quinn MA.Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden..Front Oncol2014;4:75 PMCID:PMC3988380

[119] Liu T,Xu Y.Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition..Oncol Rep2019;41:1883-92

[120] Giordano G,D’Andrea MR,Di Raimo T.JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer..J Exp Clin Cancer Res2019;38:28 PMCID:PMC6343337

[121] Mesa RA,Catalano JV,Egyed M.Simplify-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis..J Clin Oncol2017;35:3844-50 PMCID:PMC6553796

[122] Ng K,Starodub A,Yang Y.Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma..Invest New Drugs2019;37:159-65 PMCID:PMC6510909

[123] Barbie DA,Kelly K,Kawashima J.Phase 1B study of momelotinib combined with trametinib in metastatic, kirsten rat sarcoma viral oncogene homolog-mutated non-small-cell lung cancer after platinum-based chemotherapy treatment failure..Clin Lung Cancer2018;19:e853-9 PMCID:PMC6420784

[124] Padda S,Koczywas M,Kawashima J.P2.03-043 a phase 1b study of erlotinib and momelotinib for TKI-Naïve EGFR-mutated metastatic non-small cell lung cancer..J Thorac Oncol2017;12:S2143-4

[125] Mascarenhas J,Talpaz M,Stein B.Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial..JAMA Oncol2018;4:652-9 PMCID:PMC5885169

[126] Verstovsek S,Singer JW,Al-Fayoumi S.Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies..J Hematol Oncol2016;9:137 PMCID:PMC5146859

[127] Jensen KV,Aman A,Luchman HA.The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model..PLoS One2017;12:e0189670 PMCID:PMC5734728

[128] Chuang HY,Liu HW,Chiu SC.Preclinical evidence of STAT3 inhibitor pacritinib overcoming temozolomide resistance via downregulating miR-21-enriched exosomes from M2 glioblastoma-associated macrophages..J Clin Med2019;8:959 PMCID:PMC6678764

[129] Jensen KV,Aman A,Weiss S.EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo..Neuro-Oncology Adv2020;2:vdaa020 PMCID:PMC7086303

[130] Hin Tang JJ,Lim JJ.JAK/STAT signaling in hepatocellular carcinoma..Hepatic Oncol2020;7:HEP18 PMCID:PMC7137178

[131] Regenbogen T,Trinkaus K,Tan BR.Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer..J Gastrointest Oncol2017;8:985-9 PMCID:PMC5750170

[132] Iwamaru A,Iwado E,Yokoyama T.A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo..Oncogene2007;26:2435-44

[133] Ferrajoli A,Van Q,Harris D.WP1066 disrupts janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells..Cancer Res2007;67:11291-9

[134] Tsujita Y,Tasaki S,Asano T.STAT3 inhibition by WP1066 suppresses the growth and invasiveness of Qureshy et al..J Cancer Metastasis Treat2020;6:27I http://dx.doi.org/10.20517/2394-4722.2020.58 Page 17 of 18 bladder cancer cells. Oncol Rep 2017;38:2197-204

[135] Horiguchi A,Kuroda K,Asakuma J.STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma..Br J Cancer2010;102:1592-9 PMCID:PMC2883159

[136] Huang Y,Liu A,Wang X.Signal transducer and activator of transcription-3 inhibitor WP1066 affects human tongue squamous cell carcinoma proliferation and apoptosis in vitro and in vivo..Zhonghua Kou Qiang Yi Xue Za Zhi2014;49:308-13(in Chinese)

[137] Zhou X,Liu A,Zhang K.STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo..Oncol Rep2014;31:2173-80

[138] Bai H,Qi Y,Li N.Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway..BMC Cancer2019;19:454 PMCID:PMC6521381

[139] Hou J,Deng Q,Hu X.TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway..Oncol Rep2019;41:753-64 PMCID:PMC6312989

[140] Zhou Q,Zhang J,Zhou Z.Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the stat3 pathway..Cancer Manag Res2018;10:6339-55 PMCID:PMC6267774

[141] Zhou X,Liu A,Jiang Q.WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR21 axis..Sci Rep2014;4:7461 PMCID:PMC4268632

[142] Cheng CC,Wang XJ,Wan XQ.Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066..Int J Oncol2018;53:339-48

[143] Tang YJ,Wu WG,He YF.Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro..Genet Mol Res2015;14:2450-60

[144] Palagani V,El Khatib M,Giese N.Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression..Carcinogenesis2013;35:859-66

[145] Fu LX,Pan JD,Zhou TM.JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling..J Biol Regul Homeost Agents2017;31:51-8

[146] Faouzi M,Ahidouch A.Intermediate Ca2+-sensitive K+ channels are necessary for prolactin-induced proliferation in breast cancer cells..J Membr Biol2010;234:47-56

[147] Kano Y,Kawamoto K,Hayashi K.Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus..Oncol Rep2014;31:1133-8

[148] Xie L,Dai Z,Ke H.Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death..Int J Biol Sci2018;14:577-85 PMCID:PMC5968850

[149] Zhang L,Zhu J,Xue BX.ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgenindependent prostate cancer..Mol Med Rep2018;17:7045-54 PMCID:PMC5928660

[150] Wernig G,Okabe R,Leeman DS.Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera..Cancer Cell2008;13:311-20

[151] Pardanani A,Jamieson C,Talpaz M.Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis..J Clin Oncol2011;29:789-96 PMCID:PMC4979099

[152] Pardanani A,Cortes JE,Mesa RA.Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial..JAMA Oncol2015;1:643-51

[153] Harrison CN,Vannucchi AM,Tiu RV.Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study..Lancet Haematol2017;4:e317-24

[154] Li SD,Li H,Sidorenko T.Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications..Genome Med2017;9:89 PMCID:PMC5662094

[155] Zhang FQ,Duan SZ,Zhu RY.JAK2 inhibitor TG101348 overcomes erlotinib-resistance in nonsmall cell lung carcinoma cells with mutated EGF receptor..Oncotarget2015;6:14329-43 PMCID:PMC4546470

[156] Chen D,Wang J,Duan S.Biodegradable nanoparticles mediated Co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the treatment of ELTN-resistant non-small cell lung cancer (NSCLC) via suppression of the JAK2/STAT3 signaling pathway..Front Pharmacol2018;9:1214 PMCID:PMC6242943

[157] Gorshkov K,Sun W,Huang W.Quantitative chemotherapeutic profiling of gynecologic cancer cell lines using approved drugs and bioactive compounds..Transl Oncol2019;12:441-52 PMCID:PMC6302136

[158] Zhou B,Bailey ST,Jeong Y.Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal..J Clin Invest2014;124:553-63 PMCID:PMC3904607

[159] Lin C,Ren Z,Zhang C.GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC..Oncoimmunology2017;6:e1353860 PMCID:PMC5674951

[160] Genovese MC,Gottenberg JE,Bartok B.Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial..JAMA2019;322:315-25 PMCID:PMC6652745

[161] Tarrant JM,Li W,Pan Y.Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials..Rheumatol Ther2020;7:173-90 PMCID:PMC7021851

[162] Van Rompaey L,van der Aar EM,Nelles L.Preclinical characterization of GLPG0634, a selective Page 18 of 18 Qureshy et al..J Cancer Metastasis Treat2020;6:27I http://dx.doi.org/10.20517/2394-4722.2020.58 inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191:3568-77.

[163] Chuang CH,Rogers ZN,Yang D.Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis..Nat Med2017;23:291-300 PMCID:PMC6453542

[164] Huang Z,Li Y,Wang T.Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling..Theranostics2018;8:4995-5011 PMCID:PMC6217055

[165] Hexner EO,Jan M,Robinson C.Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders..Blood2008;111:5663-71 PMCID:PMC2424161

[166] Pinto N,Vizeacoumar F,Lowerison M.Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models..PLoS One2018;13:e0207152 PMCID:PMC6231667

[167] Takeuchi T,Iwasaki M,Saeki S.Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study..Ann Rheum Dis2016;75:1057-64 PMCID:PMC4893099

[168] Kivitz AJ,Poiley J,Kristy R.Peficitinib, a JAK inhibitor, in the treatment of moderate-tosevere rheumatoid arthritis in patients with an inadequate response to methotrexate..Arthritis Rheumatol2017;69:709-19

[169] Ruan Z,Cheng W.OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells..Cancer Manag Res2019;11:389-99 PMCID:PMC6314052

[170] Schwartz DM,Villarino A,Gadina M.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases..Nat Rev Drug Discov2017;17:78 PMCID:PMC6168198

[171] Levitzki A.Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction..FASEB J1992;6:3275-82

[172] Ioannidis S,Wang T,Block MH.Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway..J Med Chem2011;54:262-76

[173] Cao JJ, Hood J, Lohse D, Mak CC, McPherson A, et al. WO2007053452A1 - Bi-aryl meta-pyrimidine inhibitors of kinases. Accessed from: https://patents.google.com/patent/WO2007053452A1/el. [Accessed on 12 Aug 2020]

[174] Menet CJ,Van Lommen G,Blanc J.Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634..J Med Chem2014;57:9323-42

[175] Huang T, Xue CB, Wang A, Kong L, Ye HF, et al. WO2011112662A1 Piperidin-4-yl azetidine derivatives as jak1 inhibitors. Accessed from: https://patents.google.com/patent/WO2011112662A1/en. [Accessed on 12 Aug 2020]

[176] Thompson JE,Cummings RT,Frankshun R.Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor..Bioorganic Med Chem Lett2002;12:1219-23

[177] Gingrich DE.Synthesis and kinase inhibitory activity of 3ʹ-(S)-epi-K-252a..Bioorganic Med Chem Lett2002;12:2829-31

[178] Tyner JW,Deininger J,Aichberger KJ.CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms..Blood2010;115:5232-40 PMCID:PMC2892953

[179] William AD,Blanchard S,Teo EL.Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19- dioxa-5,7, 26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma..J Med Chem2011;54:4638-58

[180] Hamaguchi H,Moritomo A,Nakajima Y.Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor..Bioorganic Med Chem2018;26:4971-83

[181] Fridman J,Liu P,Burn T.Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders..Blood2007;110:3538

[182] Flanagan ME,Brissette WH,Casavant JM.Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection..J Med Chem2010;53:8468-84

[183] Verstovsek S,Quintás-Cardama A,Cortes J.WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation..Clin Cancer Res2008;14:788-96